Besides the well-known drug targets for RA treatment, such as IRAK1, HIF1A, and IL6ST, some HRGs, including XPO1, GATA3, MYC, and CD40, have also been indicated to serve as new candidate therapeutic targets for RA [36, 51, 52]. The gene discussed is HIF1A; the disease is rheumatoid arthritis.